Evidence map›Paper›PMID 28849371›Full record

ArticleActa neuropathologica2018

MSA prions exhibit remarkable stability and resistance to inactivation.

Amanda L Woerman, Sabeen A Kazmi, Smita Patel, Yevgeniy Freyman, Abby Oehler, Atsushi Aoyagi, Daniel A Mordes, Glenda M Halliday, Lefkos T Middleton, Steve M Gentleman and 2 more

Open access · greenAbstract read
In one paragraph

Article in Acta neuropathologica, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers.

0numbers the graph read from it
0cells of the map it votes in
64citing papers in PubMed
5.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

64 citing papers in PubMed, 92 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Colonoscopy and Subsequent Risk of Parkinson's Disease.Journal of Parkinson's disease · 2024
    Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review

4 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 4 countries.

Amanda L WoermanInstitute for Neurodegenerative Diseases, Weill Institute for Neurosciences, University of California, 675 Nelson Rising Lane, San Francisco, CA, 94158, USA.
Sabeen A KazmiInstitute for Neurodegenerative Diseases, Weill Institute for Neurosciences, University of California, 675 Nelson Rising Lane, San Francisco, CA, 94158, USA.
Smita PatelInstitute for Neurodegenerative Diseases, Weill Institute for Neurosciences, University of California, 675 Nelson Rising Lane, San Francisco, CA, 94158, USA.
Yevgeniy FreymanInstitute for Neurodegenerative Diseases, Weill Institute for Neurosciences, University of California, 675 Nelson Rising Lane, San Francisco, CA, 94158, USA.
Abby OehlerInstitute for Neurodegenerative Diseases, Weill Institute for Neurosciences, University of California, 675 Nelson Rising Lane, San Francisco, CA, 94158, USA.
Atsushi AoyagiInstitute for Neurodegenerative Diseases, Weill Institute for Neurosciences, University of California, 675 Nelson Rising Lane, San Francisco, CA, 94158, USA.
Daniel A MordesC.S. Kubik Laboratory for Neuropathology, Department of Pathology, Massachusetts General Hospital, Boston, MA, USA.
Glenda M HallidayBrain and Mind Centre, Sydney Medical School, The University of Sydney, Sydney, Australia.
Lefkos T MiddletonNeuroepidemiology and Ageing Research Unit, School of Public Health, Imperial College London, London, UK.
Steve M GentlemanDivision of Brain Sciences, Department of Medicine, Imperial College London, London, UK.
Steven H OlsonInstitute for Neurodegenerative Diseases, Weill Institute for Neurosciences, University of California, 675 Nelson Rising Lane, San Francisco, CA, 94158, USA.
Stanley B PrusinerInstitute for Neurodegenerative Diseases, Weill Institute for Neurosciences, University of California, 675 Nelson Rising Lane, San Francisco, CA, 94158, USA. stanley.prusiner@ucsf.edu.
University of California, San Francisco · USInstitute for Neurodegenerative Disorders · USImperial College London · GBMassachusetts General Hospital · USUNSW Sydney · AU

Funding

VIRAL DEGENERATIVE DEMENTING DISEASE IN AGING (SUPP)P01AG002132 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI SALI, ANDREJ · 1985 to 2024
$51.7M
THE ROLE OF ADVANCED CAA IN ALZHEIMER'S DEMENTIAP50AG005134 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI HYMAN, BRADLEY T. · 1985 to 2018
$42.1M
SYNTHETIC AND RECOMBINANT PRP PEPTIDES AND PROTEINSP01AG010770 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PRUSINER, STANLEY B · 1993 to 2015
$30.3M
Towards Therapeutics for Neurodegenerative DiseasesR37AG031220 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PRUSINER, STANLEY B · 2008 to 2017
$6.2M
NIA NIH HHS AG002132NIA NIH HHS AG031220NIA NIH HHS P01 AG002132NIA NIH HHS P01 AG010770NIA NIH HHS P50 AG005134NIA NIH HHS R37 AG031220
6 · The paper itself

Abstract

In multiple system atrophy (MSA), progressive neurodegeneration results from the protein α-synuclein misfolding into a self-templating prion conformation that spreads throughout the brain. MSA prions are transmissible to transgenic (Tg) mice expressing mutated human α-synuclein (TgM83

Indexed as

alpha-SynucleinAnimalsBiological TransportBrainDetergentsDisease Models, AnimalFixativesFormaldehydeHEK293 CellsHumansMice, TransgenicMultiple System AtrophyMuscle, SkeletalMutationPrionsProtein Aggregatesalpha-SynucleinDetergentsFixativesFormaldehydePrionsProtein AggregatesSarcosinesarkosylSNCA protein, humanStainless SteelNeurodegenerationPropagationProteinopathiesTransmission modelsα-synuclein

Identifiers

PMID28849371
PMCPMC5756500
OpenAlexW2749912201

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.